Q32 Bio (QTTB) Return on Invested Capital (2024 - 2025)
Q32 Bio's (QTTB) quarterly Return on Invested Capital came in at 0.04% in Q2 2025, up 12.0% year-on-year from 0.04% in Q2 2024, and up 40.89% quarter-over-quarter from 0.07% in Q1 2025.
Q32 Bio (QTTB) Return on Invested Capital (2024 - 2025) Analysis & Trends
Q32 Bio's Return on Invested Capital history runs 2 years deep, the most recent figure standing at 0.04% for Q2 2025.
- On a quarterly basis, Return on Invested Capital rose 12.0% year-over-year to 0.04% in Q2 2025; TTM through Jun 2025 was 0.04%, a 12.0% increase from a year earlier, with the FY2024 full-year figure at 0.33%, changed N/A from the prior year.
- Return on Invested Capital climbed to 0.04% in Q2 2025 per QTTB's latest filing, from 0.07% in the prior quarter.
- Across five years, Return on Invested Capital topped out at 0.04% in Q2 2025 and bottomed at 0.23% in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 69,146.49 Bn | 69,146.20 Bn | - | - |
| 2 | Nanobiotix | 1,942.19 Bn | 1,942.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 475.42 Bn | 470.63 Bn | 1.35 Bn | 0.00% |
| 5 | Vertex Pharmaceuticals | 123.32 Bn | 116.08 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.80 Bn | 61.04 Bn | 3.31 Bn | 0.04% |
| 7 | Belite Bio | 63.28 Bn | 63.28 Bn | - | - |
| 8 | Argenx Se | 56.67 Bn | 51.48 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 38.15 Bn | 38.15 Bn | - | - |
| 10 | Q32 Bio | 229.19 Mn | 178.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -0.04% |
| Mar 31, 2025 | -0.07% |
| Dec 31, 2024 | -0.10% |
| Sep 30, 2024 | -0.16% |
| Jun 30, 2024 | -0.17% |
| Mar 31, 2024 | -0.23% |